Valuation: GENinCode Plc

Market Cap 4.71M 6.29M 5.62M 5.18M 8.83M 596M 8.97M 62.41M 24.58M 312M 23.61M 23.11M 989M P/E 2026 *
-0.88x
P/E 2027 * -
Enterprise Value 4.41M 5.89M 5.26M 4.85M 8.27M 558M 8.39M 58.43M 23.02M 292M 22.11M 21.63M 926M EV / Sales 2026 *
1.38x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 day-3.85%
Current month-10.71%
1 month-28.57%
3 months-21.88%
6 months-47.92%
Current year-73.96%
1 week 0.56
Extreme 0.561
0.7
1 month 0.56
Extreme 0.561
0.9
Current year 0.56
Extreme 0.561
2.5
1 year 0.56
Extreme 0.561
4.9
3 years 0.56
Extreme 0.561
10
5 years 0.56
Extreme 0.561
40
10 years 0.56
Extreme 0.561
48
Manager TitleAgeSince
Chief Executive Officer 62 06/09/2018
Chief Operating Officer 51 06/09/2018
Director of Finance/CFO 57 01/11/2020
Director TitleAgeSince
Director/Board Member 57 01/04/2021
Chairman 62 06/09/2018
Chairman 72 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
06/05/26 Free

Founder

30,428,453 4.0407%
06/05/26 Free

Chairman

1,267,852 0.1684%
06/05/26 Free

Chief Financial Officer

13,523,757 1.7959%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%0.00%-82.64%-92.42% 6.29M
+1.99%-2.07%-19.88%+5.92% 177B
+3.83%+1.19%+0.72%+32.86% 118B
+3.19%+4.72%-20.93%+15.58% 118B
+1.93%+19.13%-43.11%+8.64% 91.21B
-0.57%-0.86%+2.32%+79.33% 64.59B
-1.10%+1.68%+13.42%+79.86% 56.13B
+3.13%+3.44%+6.54%-22.51% 54.59B
+2.40%+3.58%-10.57%+32.73% 43.6B
+3.43%+4.93%-5.06%-10.63% 33.95B
Average +1.43%+3.68%-15.92%+12.94% 75.75B
Weighted average by Cap. +2.18%+3.77%-12.16%+22.45%

Financials

2026 *2027 *
Net sales 3.2M 4.27M 3.81M 3.52M 6M 405M 6.09M 42.39M 16.7M 212M 16.04M 15.7M 672M -
Net income -5.06M -6.76M -6.04M -5.57M -9.49M -641M -9.64M -67.11M -26.44M -336M -25.39M -24.85M -1.06B -
Net Debt -300K -401K -358K -330K -563K -37.98M -571K -3.98M -1.57M -19.9M -1.51M -1.47M -63.04M -
Projected Income Statement - Annual - GENinCode Plc
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
22/10/26 GBX 0.6250 -3.85% 564,505
21/10/26 GBX 0.6500 -3.70% 4,233,806
20/10/26 GBX 0.6750 +12.50% 3,865,642
19/10/26 GBX 0.6000 -4.00% 1,374,835
16/10/26 GBX 0.6250 0.00% 79,436
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.006250GBP
Average target price
0.0750GBP
Spread / Average Target
+1,100.00%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - GENinCode Plc
  1. Stock Market
  2. Stocks
  3. GENI Stock